Comparative analysis of curative efficacy and prognostic factors across treatment modalities for early-stage hepatocellular carcinoma (BCLC 0/A)

Table 2 Analysis of factors associated with overall survival in patients with Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma, n (%)

Variables		n (n = 102)	5-year OS	χ2	P value
Age (year)	60	73	42 (57.53)	1.000	0.819
	> 60	29	42 (57.54)
Gender	Male	77	42 (57.55)	1.000	0.109
	Female	25	42 (57.56)
LC	No	26	42 (57.57)	1.000	0.871
	Yes	76	42 (57.58)
HBV infection	No	23	42 (57.59)	1.000	0.910
	Yes	79	42 (57.60)
AFP (μg/L)	≤ 400	86	42 (57.61)	1.000	0.442
	> 400	16	42 (57.62)
PS score	0	69	42 (57.63)	2.000	0.290
	1	27	42 (57.64)
	2	6	42 (57.65)
Child-Pugh classification	A	90	42 (57.66)	1.000	0.425
	B	12	42 (57.67)
Number of tumor	1	94	42 (57.68)	1.000	0.871
	2	8	42 (57.69)
Diameter of tumor (cm)	≤ 2	46	42 (57.70)	1.000	0.444
	2-3	56	42 (57.71)
BCLC	0	43	42 (57.72)	1.000	0.444
	A	59	42 (57.73)
TBIL (μmol/L)	≤ 22	100	42 (57.74)	0.058	0.809
	> 22	2	42 (57.75)
ALB (g/L)	≥ 35	99	42 (57.76)	0.304	0.157
	< 35	3	42 (57.77)
ALT (U/L)	≤ 50	58	42 (57.78)	1.000	0.774
	> 50	44	42 (57.79)
AST (U/L)	≤ 59	100	42 (57.80)	1.000	0.963
	> 59	2	42 (57.81)
GGT (U/L)	≤ 73	100	42 (57.82)	1.000	0.769
	> 73	2	42 (57.83)
ICG-R15 (%)	≤ 10	100	42 (57.84)	1.000	0.963
	> 10	2	42 (57.85)
PLT (× 109/L)	≥ 100	99	42 (57.86)	1.000	0.267
	< 100	3	42 (57.87)
Treatment modalities	RFA	40	42 (57.88)	7.024	0.03
	LR	30	42 (57.89)
	Combined	32	42 (57.90)

OS: Overall survival; BCLC: Barcelona Clinic Liver Cancer; LC: Liver cirrhosis; HBV: Hepatitis B virus; AFP: Alpha fetoprotein; PS: Performance status; TBIL: Total bilirubin; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ICG-R15: Indocyanine green retention rate at 15 minutes; PLT: Platelet count.